Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

Kshitij Wagh(Los Alamos National Laboratory), Michael S. Seaman(Beth Israel Deaconess Medical Center)

PLoS Pathogens

March 30, 2016

10.1371/journal.ppat.1005520

Cited by 200

Related Papers

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

|New England Journal of Medicine|2020|1.4k

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

|Vaccine|2011|308

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

|The Lancet|2017|196

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

|Science Translational Medicine|2011|183

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

|The Journal of Infectious Diseases|2012|168